Published on: December 18, 2019 at 10:30PM
Conditions: Type2 Diabetes; Insulin Sensitivity
Interventions: Drug: Empagliflozin 25 MG; Drug: Placebo oral tablet
Sponsors: University of Virginia; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
https://ift.tt/2sA6U77
Wednesday, 18 December 2019
New diabetes clinical trial: Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Nothing happens without a Reason
Make Something out of it.